3T MRI Biomarkers of Glioma Treatment Response

Status Terminated

Clinical Trial Summary

This pilot clinical trial studies advanced magnetic resonance imaging (MRI) techniques in measuring treatment response in patients with high-grade glioma. New diagnostic procedures, such as advanced MRI techniques at 3 Tesla, may be more effective than standard MRI in measuring treatment response in patients receiving treatment for high-grade gliomas.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To correlate treatment-induced changes in quantitative MRI-based biomarkers—specifically, those sensitive to tumor protein content (amide proton transfer asymmetry [APTasym] from chemical exchange saturation transfer [CEST]), cellularity (apparent diffusion coefficient [ADC] from diffusion-weighted imaging [DWI]), and blood flow (volume transfer constant [K^trans] from dynamic contrast-enhanced [DCE]; cerebral blood flow [CBF] from dynamic susceptibility contrast [DSC])—with treatment-induced changes in tumor size, measured via standard anatomic MRI.

II. To correlate treatment-induced changes in the above quantitative MRI endpoints with patient progression-free survival (PFS).

OUTLINE:

Patients undergo measurement of tumor protein content using CEST-MRI, cellularity using DWI-MRI, and blood flow using DCE-MRI and DSC-MRI within 2 weeks of treatment and at 2 and 4 weeks after initiation of treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01996527
Study type	Interventional
Source	Vanderbilt-Ingram Cancer Center
Contact
Status	Terminated
Phase	Early Phase 1
Start date	May 2012
Completion date	January 1, 2016

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02530502` - Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma	Phase 1
Withdrawn	`NCT02194452` - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors	N/A
Completed	`NCT00238303` - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	Phase 2
Completed	`NCT02227901` - Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Phase 1
Completed	`NCT00049387` - Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma	Phase 1
Completed	`NCT02015819` - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas	Phase 1
Active, not recruiting	`NCT02179086` - Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma	Phase 2
Recruiting	`NCT04573140` - A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)	Phase 1
Active, not recruiting	`NCT00823797` - Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma	Phase 2
Completed	`NCT00045565` - Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma	Phase 1
Completed	`NCT01977677` - Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma	Phase 1/Phase 2
Completed	`NCT01648348` - Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme	Phase 1/Phase 2
Completed	`NCT00004262` - Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme	Phase 1
Terminated	`NCT01575275` - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme	Phase 2
Terminated	`NCT01103375` - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma	Phase 1
Completed	`NCT01119599` - RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma	Phase 1
Completed	`NCT01131234` - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00459381` - Pazopanib in Treating Patients With Recurrent Glioblastoma	Phase 2
Completed	`NCT00316849` - Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Phase 1
Terminated	`NCT00006773` - Bortezomib in Treating Patients With Recurrent Glioma	Phase 1